Chemotherapy-induced febrile neutropenia: About 200 episodes. Clinical, microbiological and therapeutic characteristics;Les neutropénies fébriles chimio-induites : à propos de 200 épisodes. Profil clinique, microbiologique et thérapeutique

Pathologie Biologie

Volumn 56, Issue 3, 2008, Pages 154-157

  Gharbi, O ^a   Ben Hadj Hassen, S ^a   Kaabia, N ^a   Limam, S ^a   Hadj Amor, M ^a   Ben Fatma, L ^a   Landolsi, A ^a   Hochlef, M ^a   Letaief, A ^a   Boukadida, J ^a   Ben Ahmed, S ^a  

^a FARHAT HACHED HOSPITAL   (Tunisia)

Author keywords

Fever; Neoplasm; Neutropenia

Indexed keywords

AMIKACIN; ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; CEFOTAXIME; COLONY STIMULATING FACTOR; IMIPENEM;

ADULT; AGED; ARTICLE; BACTERIUM IDENTIFICATION; BLOOD CULTURE; BODY TEMPERATURE; CLINICAL FEATURE; COAGULASE NEGATIVE STAPHYLOCOCCUS; COST OF ILLNESS; DIABETES MELLITUS; DISEASE DURATION; ESCHERICHIA COLI; FEBRILE NEUTROPENIA; HOSPITALIZATION; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MEDICAL DOCUMENTATION; SOLID TUMOR; URINE CULTURE;

ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS; BACTERIAL INFECTIONS; CHILD; CHILD, PRESCHOOL; FEVER; HUMANS; INFANT; MIDDLE AGED; NEOPLASMS; NEUTROPENIA; RETROSPECTIVE STUDIES;

EID: 42249085252     PISSN: 03698114     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.patbio.2007.09.025     Document Type: Article

References (13)

1. Picazo J.J. Management of the febrile neutropenic patient: a consensus conference. Clin Infect Dis 39 (2004) 51-56
2. Pizzo P.A., Meyers J., and Freifeld A.G. Infection in the cancer patient. In: De Vita V.H. (Ed). Cancer: principles and practice of oncology. 4th ed. (1993), Lippincott-Raven, Philadelphia, PA 2292-2337
3. Crawford J., Dale D.C., and Lyman G.H. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer 100 (2004) 228-237
4. Lyman G.H., Dale D.C., and Crawford J. Risk models for the prediction of chemotherapy induced neutropenia (CIN) and its consequences: a systematic review and classification. Blood 98 (2001) 413b
5. Blay J.Y., Ray-Coquard I., Mermet C., Maugard C., Ravaud A., Malet M., et al. A multicentric prospective study of prognostic factors for febrile neutropenia after chemotherapy in general and cancer hospital. J Clin Oncol 16 (1997) 56a
6. Choi C.W., Sung H.J., Park K.H., Yoon S.Y., Kim S.J., Oh S.C., et al. Early lymphopenia as a risk factors for chemotherapy-induced febrile neutropenia. Am J Hematol 73 (2003) 263-266
7. Yoshida M., and Ohno R. Antimicrobial prophylaxis in febrile neutropenia. Clin Infect Dis 39 Suppl. 1 (2004) S65-S67
8. Berghmans T., Paesmans M., Lafitte J.J., Mascaux C., Meert A.P., Jacquy C., et al. Therapeutic use of granulocyte and granulocyte-macrophage colony-stimulating factors in febrile neutropenic cancer patients. A systematic review of the literature with meta-analysis. Support Care Cancer 10 (2002) 181-188
9. Lyman G.H., Kuderer N.M., and Djulbegovic B. Prophylactic granulocyte colony-stimulating in patients receiving dose-intensive cancer chemotherapy: a meta-analysis. Am J Med 112 (2002) 406-411
10. Blay J.Y., Le Cesne A., Blanc-Vincent M.P., Fervers B., Latour J.P., and Philip T. Standards, options, and recommendations for the use of hematopoietic growth factors in oncology. Presse Med 29 (2000) 2004-2008
11. Ray-Coquard I., Borg C., Bachelot T., Fayette J., Zufferey L., Guastalla J.P., et al. Facteurs pronostiques des neutropénies febriles. Bull Cancer 93 5 (2006) 501-506
12. Lionne- Huyghe P., Kuhnowski F., Coiteux V., Bauters F., and Morschhauser F. Indications des facteurs de croissance granulocytaires en hématologie. Bull Cancer 93 5 (2006) 453-462
13. Crawford J., Ozer H., Stoller R., Johnson D., Lyman G., Tabbara I., et al. Reduction by granulocyte colony-stimulating factor of fever and neutopenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 325 (1991) 164-170